Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...
Tag: SPDR S&P Biotech ETF
The Bulls Still Own This Market. But Cracks Are Starting to Show.
Text size Riskier and more speculative pockets of the market have led the rally, which has coincided with a decline in bond yields. NYSE If it looks like a bull market and acts like a bull market, it’...
Turning Point Stock Doubles on Bristol Deal. What It Means for Biotech M&A.
Text size Photograph by Georges Gobet/AFP/Getty Images Turning Point Therapeutics stock has more than doubled after Bristol Myers Squibb announced that it had agreed to buy the company. It’s just the ...
Big Pharma Has Enough Cash to Buy All of Biotech. Why M&A Isn’t Happening.
Text size Late last year, Barron’s predicted a wave of deals, citing biotech companies’ cash holdings. Above, the plates used to print one-dollar bills. Alex Wong/Getty Images With biotech...
Biotech Stocks Are Due to Bounce Back. This One Stands Out.
Text size Large-cap biotech will offer a smoother ride than small, and Vertex, in particular, looks attractive. Igor Akimov/Dreamstime.com Biotech stocks began the year in much the same way they ended...